StockWatch
·

Kwality Pharmaceuticals Ltd

BSE: 539997

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
181.94
+11.6%+62.1%
Expenditure
139.72
+8.3%+49.0%
Net Profit
29.02
+13.3%+105.6%
OPM %
27.49%
+2.22pp+4.71pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0050.94101.89152.83203.77Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Strong Quarter, Concentrated Growth, Unproven Multiyear Roadmap

bioequivalence · MENA expansion · hormone plant

Result verdictFollow-upQ2 FY2716 Nov 20266 minPharma & Healthcare

Strong delivery, bold ₹1,500 Cr FY30 vision with concrete milestones

bioequivalence pipeline · MENA expansion · hormone commercialization

TranscriptDeep diveQ2 FY2716 Nov 20266 minPharma & Healthcare

Kwality Pharma Q2FY27: consol PAT doubles YoY to ₹29 Cr, margins expand, guidance raised

pharmaceuticals · margin expansion · guidance raised

ResultsQ2 FY2712 Nov 20263 minPharma & Healthcare
Latest
Board Meeting12 Nov, 12:56 pm

Kwality Pharma Q2FY27: consolidated PAT jumps 106% YoY to ₹29 Cr, margins expand to 16%

Kwality Pharmaceuticals' consolidated Q2FY27 print was strong on both lines: revenue of ₹181.22 Cr grew 63.2% YoY (₹111.05 Cr) and 11.6% QoQ (₹162.35 Cr), while PAT of ₹29.03 Cr rose 105.6% YoY (₹14.12 Cr) and 13.3% QoQ (₹25.62 Cr) — figures from the audited P&L tables (standalone PAT ₹29.02 Cr, EPS ₹27.97, tracks consolidated almost exactly, confirming the African subsidiary's minimal contribution). No one-off items sat in either the current or year-ago quarter, so the growth is clean and organic rather than base-effect driven. Against management's own FY27 outlook — ₹700 Cr+ reaffirmed at the Q1 call — this print prompted a further guidance raise to ₹720 Cr+; H1FY27 revenue of ₹343.58 Cr now needs roughly ₹376 Cr in H2 to hit the new target, a bar the ~11-12% sequential pace of the last two quarters puts within reach, so the quarter reads as a beat against the company's own plan. Kwality carries no formal analyst coverage (confirmed via search and flagged in our pre-result preview), so there is no Street consensus to grade against; our own pre-print expectation of ₹180-190 Cr revenue was met at the low end on actual revenue of ₹181 Cr. Margins did the heavier lifting this quarter: EBITDA margin (OPM) expanded to ~27.5% from 22.8% YoY and 25.3% QoQ, and PAT margin to 15.95% from 12.6% YoY and 15.7% QoQ — both within or just above management's standing 26-27% EBITDA-margin band, which the MD&A attributes to improved operating leverage and a more favourable product mix. The quarter's corporate actions reinforce the regulated-market push behind that margin trend: EU-GMP certification from Hungary for the Cephalosporin and Oncology units (Nov 5) deepens access to high-value regulated markets, and the 4-acre Amritsar land purchase (Oct 19) for a new Unit 7 (4+ injectable lines, 6+ OSD lines) extends capacity toward the stated FY30 ambition of ₹1,500 Cr revenue. Working-capital discipline improved alongside the P&L, with debtor days down to 178 from 203 in FY26 and the cash-conversion cycle down to 130 days from 170 — supporting the cash generation needed to fund the capex ramp.

12 Nov 2026, 12:56 pm

Quarterly Result10 Aug, 12:11 pm

Kwality Pharma Q1FY27: consolidated PAT surges 115% YoY to ₹25.6 Cr, margins expand, guidance raised

Kwality Pharmaceuticals posted consolidated revenue of ₹162.35 Cr in Q1FY27, up 45.6% YoY from ₹111.48 Cr and up 3.3% QoQ from ₹157.11 Cr. Consolidated PAT rose to ₹25.62 Cr from ₹11.92 Cr a year ago (+115% YoY; +1.2% QoQ), with net margin expanding to 15.7% from 10.7% YoY. No exceptional items sit in either the current or year-ago quarter, so the growth is clean/organic rather than base-effect driven. Standalone tracks consolidated almost exactly this quarter (PAT ₹25.63 Cr, EPS ₹24.70 vs consolidated EPS ₹24.69) — the foreign subsidiary contributes negligibly. The margin expansion is EBITDA-led: EBITDA rose to ₹41 Cr from ₹37 Cr YoY (+13%), with OPM widening to ~25.3% from 21.7% a year ago and 24.8% last quarter, which management attributes to operating leverage and a mix shift toward higher-margin regulated-market and oncology products rather than to lower input costs or other income (other income was flat at ₹0.62 Cr). There is no independent street coverage or consensus estimate available for this small-cap (~₹335 Cr market cap) name, so vs-street cannot be assessed; the only outside benchmark is management's own prior quarterly pacing guide of ₹150-160 Cr for Q1, which the ₹162.35 Cr print exceeds. Against the FY26-concall guidance of FY27 revenue ₹650-700 Cr and EBITDA margin 26-27%, this quarter's run-rate is tracking ahead — management used this print to raise full-year guidance to revenue ₹700+ Cr, EBITDA ₹189-196+ Cr (27-28%+ margin) and PAT ₹109+ Cr (~15.5%+ margin), i.e., the company itself signals the quarter beat its own plan. Operationally, the quarter's R&D output (13 bioequivalence studies completed toward a 40-molecule pipeline, filings live in 15+ countries) and 15+ new product registrations across Malaysia, Algeria, Peru and Mexico support the regulated-market push cited as the margin driver; CDSCO clearance for Pembrolizumab pre-clinical batches adds a second biologics candidate behind Erythropoietin, which management flagged in the prior concall as a long-term margin lever via the FY29 hormones/biologics revenue ambition. The Hormone facility remains on schedule for a November 2026 completion, the next concrete checkpoint against that plan.

10 Aug 2026, 12:11 pm

Corporate Events

Board MeetingKPL
2026
12Nov

Board Meeting

To consider and approve the Unaudited Standalone and Consoli…

BSE Filing ↗
Board MeetingKPL
2026
31Aug

Board Meeting

The 43rd Annual General Meeting (AGM) of the Shareholders of…

BSE Filing ↗
Board MeetingKPL
2026
10Aug

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingKPL
2026
30Jun

Board Meeting

The Board of Directors considered and approved the standalon…

BSE Filing ↗
Board MeetingKPL
2024
23May

Board Meeting

Consider and approve the Standalone & Consolidated audited f…

BSE Filing ↗
Board MeetingKPL
2024
6Feb

Board Meeting

Consider and approve Standalone and Consolidated Unaudited F…

BSE Filing ↗
Board MeetingKPL
2023
4Nov

Board Meeting

Consider and approve the Unaudited Standalone and Consolidat…

BSE Filing ↗
Board MeetingKPL
2023
10Aug

Board Meeting

Consider and approve the Standalone and Consolidated Unaudit…

BSE Filing ↗